An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression ...

WASHINGTON -- Semaglutide (Wegovy) improved liver inflammation and fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH) through both weight loss-related and direct ...

Scientists have failed to show that weight-loss wonder drug semaglutide slows the progress of Alzheimer's disease (AD), as ...

Both semaglutide and tirzepatide are associated with improvements in quality of life for adults with obesity, though ...

Two large-scale phase 3 trials found that semaglutide did not significantly slow cognitive decline in early-stage Alzheimer’s ...

Semaglutide reduced liver fibrosis and resolved MASH in the ESSENCE trial, offering dual hepatic and metabolic benefits. Read ...

An older oral version of the company's semaglutide drug failed to meet its main goal in late-stage trials testing whether the ...

In a large real-world analysis across three U.S. healthcare databases, semaglutide and tirzepatide showed cardiovascular benefits consistent with randomized trials. Semaglutide lowered heart attack ...

Trials of semaglutide, the active ingredient in Ozempic and Wegovy, improve Alzheimer’s biomarkers but do not slow disease ...

Novo Nordisk shares plunge after its oral semaglutide Alzheimer’s trials fail, raising fresh doubts over its push into a ...

This article was reviewed by Darragh O’Carroll, MD. Semaglutide Side Effects: What to Know Key takeaways: Common semaglutide ...

In a setback to hopes of finding new treatment options for dementia, drug maker Novo Nordisk has confirmed that ...